Diamyd Medical
1.27 SEK
+1.60 %
Less than 1K followers
DMYD B
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Diamyd Medical
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 1.6 | 0.3 | 0.3 | 0.5 | 0.6 | 0.1 | 0.1 |
| growth-% | -78.3 % | -25.8 % | 77.9 % | 22.2 % | -76.4 % | 0.0 % | |
| EBITDA | -36.4 | 9.9 | -85.1 | -110.6 | -100.0 | -135.6 | -176.7 |
| EBIT | -36.6 | 9.7 | -85.9 | -114.9 | -104.9 | -146.6 | -183.2 |
| Profit before taxes | -36.6 | 9.7 | 60.0 | -103.5 | -100.2 | -151.9 | -169.8 |
| Net income | -36.6 | 9.7 | 60.0 | -103.5 | -100.2 | -151.9 | -169.8 |
| EPS | -0.51 | 0.14 | 0.82 | -1.36 | -1.29 | -1.59 | -1.50 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | 0.0 % | 0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -2,323.3 % | 2,899.7 % | -33,635.6 % | -24,566.7 % | -18,181.8 % | -104,292.3 % | -135,946.2 % |
| EBIT-% | -2,332.2 % | 2,856.0 % | -33,944.7 % | -25,542.2 % | -19,080.0 % | -112,746.2 % | -140,953.8 % |
| ROE | -58.3 % | 13.4 % | 31.7 % | -48.3 % | -54.1 % | -104.1 % | -60.6 % |
| ROI | -49.3 % | 10.8 % | 29.8 % | -43.8 % | -48.7 % | -70.0 % | -48.1 % |